Although the mice did not develop paresis at this dosage, they did develop a sensory neuropathy that was ameliorated with concurrent pharmacological inhibition of mitochondrial Na+/Ca2+-exchangers. Here, SLC8A1 is linked to sensory peripheral neuropathy.